Clinical trials: Tobacco Smoking Cessation
Tobacco Dependence
Nicotine Pharmacodynamics With a New Oral Nicotine Replacement Therapy and Nicotine Gum
A comparison of two products for oral nicotine replacement with respect to relief of urges to smoke after single doses of nicotine.
- Trial name
- NCT01368016
- Testing
- Nicotine
- Where
- 2 sites in Sweden
- Volunteers
- 346 people
- Sponsor
- McNeil AB
Tobacco Use Disorder, Substance Use Disorders
A Digital Smoking Cessation Intervention for Adults With Substance Use Disorder
Adults with substance use disorder (SUD) tend to have started smoking at a younger age and are more likely to be heavy smokers. Due to the many conflicting priorities in this population, smoking cessation is often relegated and…
- Trial name
- NCT04419922
- Testing
- Smartphone Contingency Management Intervention
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- BrightView LLC
Nicotine Addiction, Drug Addiction
Clinical Trial of Smoking Cessation Mobile Phone Program
The Sponsor is doing a research study to assess the effects of a smartphone program designed to help users smoke less and eventually quit. When participants join, their involvement in the core study will last 8 weeks.
- Conditions
- Nicotine Addiction, Drug Addiction, Drug Dependence, Substance Use Disorder
- Trial name
- NCT02656745
- Testing
- Mobile Smoking Cessation Solution
- Where
- United States
- Volunteers
- 416 people
- Sponsor
- Click Therapeutics, Inc.
Smoking Cessation
Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5 mg/Day or 20 mg/Day, Versus Placebo, as an Aid to Smoking Cessation (STRATUS US)
The primary study objective was to assess the efficacy of 2 fixed doses of rimonabant versus placebo on abstinence from tobacco use in cigarette smokers.
- Trial name
- NCT00358228
- Testing
- Rimonabant
- Where
- United States
- Volunteers
- 787 people
- Sponsor
- Sanofi
Smoking Cessation
Pharmacoeconomic Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies
The purpose of this study is to look at pharmacoeconomic data for subjects that have received either NicVAX or placebo in the Nabi-4514 or Nabi-4515 studies.
- Trial name
- NCT01178346
- Testing
- NicVAX vaccine
- Where
- 25 sites in United States
- Volunteers
- 500 people
- Sponsor
- Nabi Biopharmaceuticals
Smoking Cessation, Harm Reduction
Assisting Smokers to Switch to a JUUL E-Cigarette by Devaluing Combustible Cigarettes
This study will evaluate a reward devaluation strategy in which smokers use the JUUL e-cigarette immediately before any combustible cigarettes (CCs) are smoked.
- Conditions
- Smoking Cessation, Harm Reduction, E-Cig Use, Cigarette Smoking
- Trial name
- RECON (NCT04188197)
- Testing
- JUUL
- Where
- 2 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Rose Research Center, LLC
Smoking Cessation
A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation
The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo and Zyban for smoking cessation.
- Trial name
- NCT00141206
- Testing
- varenicline (CP-526,555)
- Where
- 20 sites in United States
- Volunteers
- 1,005 people
- Sponsor
- Pfizer
Smoking Cessation
A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation
The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo and Zyban for smoking cessation.
- Trial name
- NCT00143364
- Testing
- varenicline (CP-526,555)
- Where
- 15 sites in United States
- Volunteers
- 1,005 people
- Sponsor
- Pfizer
Smoking Cessation
A Study of Cytisinicline for Smoking Cessation in Adult Smokers
This placebo-controlled Phase 3 study is being conducted at sites within the United States to evaluate 3 mg cytisinicline 3 times daily (TID) for treatment duration of 42 days/6 weeks and evaluate 3 mg cytisinicline TID for…
- Trial name
- ORCA-2 (NCT04576949)
- Testing
- Cytisinicline, Behavioral support
- Where
- 17 sites in United States
- Volunteers
- 810 people
- Sponsor
- Achieve Life Sciences